Page 15 - MemoriaEHD-Eng

www.ciberehd.org

P2. Viral Hepatitis

í
Program Coordinator:

Dr. Juan Ignacio Esteban Mur

Associate Coordinators:

Drs. Xavier Forns y Manuel Romero Gómez

Area 2 includes 8 research groups led by Drs. Juan Ignacio Esteban Mur (Hospital
Description
íñ
Universitari Vall d’Hebron. Barcelona), Rafael Esteban Mur(Hospital Universitari Vall

d’Hebron. Barcelona), Xavier Forns Bernhardt (Hospital Clínic de Barcelona), Javier
Garca-Samaniego Rey (Hospital Carlos III. Madrid), Jordi Gómez Castilla (CSIC

Instituto Lopez Neyra. Granada), Manuel Romero Gómez (Hospital Universitario de

Valme, Sevilla), Javier Salmeron Escobar (Hospital Universitario San Cecilio. Gra-
nada) and Marisa Garca Buey (Hospital de la Princesa. Madrid).
óó

During 2013 the Viral Hepatitis Program groups have consolidated the collaboration
ó
efforts previously planned.

• Public HBV database named CIBERHEP, owned by Ciberehd is open to all Na- ó
tional Health professionals willing to participate in the Project. The database

coordinated by Drs. M. Buti and R. Esteban received approval in the Boletín

Oficial del Estado BOE-B-2010-32871 Sept 25th 2010, and was registered in
the Agencia Espaola de Proteccin de Datos (AEPD), Oct 22nd 2010. CIBER-

HEP is fully active and above 1000 patients have been introduced.

• The use of new technologies such as GWAS, Ultra-deep pyrosequencing

(UDPS) using the 454/Roche platform and structural RNA biosensors using
microarrays, have allowed to publish several papers in collaboration and open
13
new research lines.
20
T
• A CDTI (Centro para el Desarrollo Tecnolgico Industrial) project in collabora- OR
P
tion with Roche Diagnostics and ABL granted by the MINECO IDI-20110115 RE
has been successfully developed (Coordinated by Dr.J.I.Esteban). This project L
A
entitled “Estudios de quasiespecies de los virus de la hepatitis B y C (VHB y NU
VHC) y de polimorfismos genmicos asociados a la respuesta al tratamiento N
A
antiviral por pirosecuenciacin” started on March 1st 2010 until December D /
H
31st, 2013. The Project have involved the consortium of four Institutions: E
Roche Diagnostic Systems, ABL-Therapy Edge, Ciberehd, and VHIR-HUVH. ER
IB
The most prominent result, has been the development of an European Patent C

EP13382278 owner by Ciberehd, Roche and VHIR based on the HCV subtyping 15
using massive sequencing.